$5.4 Billion Worldwide Migraine Drugs Industry to 2027 - Players Include Merck & Co, Novartis, Pfizer and Sanofi - ResearchAndMarkets.com
11 Jan 2023
DUBLIN--(BUSINESS WIRE)--The "Migraine Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
'Migraine Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027'
The global migraine drugs market size reached US$ 3.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 5.4 Billion by 2027, exhibiting a CAGR of 5.57% during 2021-2027.
Companies Mentioned
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Migraine is a neurological condition that causes unilateral or throbbing pain in the forehead, side of the head or around the eyes. The pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia and phonophobia. Migraine is generally diagnosed by examining the patient's medical history and symptoms, as well as by performing blood tests, and magnetic resonance imaging (MRI) and computerized tomography (CT) scans.
At present, over the counter (OTC) medicines and prescribed injections are available to relieve the symptoms and reduce the frequency and severity of migraine attacks. These drugs are either taken regularly or during attacks or exacerbations of chronic pain.
A significant rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Apart from this, the improvement in reimbursement policies for migraine medications, along with the escalating demand for precision medicines, is also contributing to the market growth.
Furthermore, the growing demand for electrical nerve stimulating devices to treat migraine and the expected approval of new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also driving the market growth. However, a decline in clinical visits and procedural treatment of migraines due to social distancing norms has impacted the market growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global migraine drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on treatment type, drug type, route of administration and distribution channel.
Breakup by Treatment Type:
Abortive Treatment
Preventive Treatment
Breakup by Drug Type:
Triptans
NSAIDs
Acetylcholine Inhibitors/ Neurotoxins
Ditans
CGRP mAbs
Others
Breakup by Route of Administration:
Oral
Injectable
Others
Breakup by Distribution Channel:
Hospital-Based Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Key Questions Answered in This Report:
How has the global migraine drugs market performed so far and how will it perform in the coming years?
What are the key regional markets?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global migraine drugs market and who are the key players?
What is the degree of competition in the industry?
For more information about this report visit https://www.researchandmarkets.com/r/54d3a3
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.